Literature DB >> 28121834

PaO2/FIO2 Ratio Derived From the SpO2/FIO2 Ratio to Improve Mortality Prediction Using the Pediatric Index of Mortality-3 Score in Transported Intensive Care Admissions.

Samiran Ray1, Libby Rogers, Christina Pagel, Sainath Raman, Mark J Peters, Padmanabhan Ramnarayan.   

Abstract

OBJECTIVES: To derive a relationship between the SpO2/FIO2 ratio and PaO2/FIO2 ratio across the entire range of SpO2 values (0-100%) and to evaluate whether mortality prediction using the Pediatric Index of Mortality-3 can be improved by the use of PaO2/FIO2 values derived from SpO2/FIO2.
DESIGN: Retrospective analysis of prospectively collected data.
SETTING: A regional PICU transport service. PATIENTS: Children transported to a PICU.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The relationship between SpO2/FIO2 and PaO2/FIO2 across the entire range of SpO2 values was first studied using several mathematical models in a derivation cohort (n = 1,235) and then validated in a separate cohort (n = 306). The best SpO2/FIO2-PaO2/FIO2 relationship was chosen according to the ability to detect respiratory failure (PaO2/FIO2 ≤ 200). The discrimination of the original Pediatric Index of Mortality-3 score and a derived Pediatric Index of Mortality-3 score (where SpO2/FIO2-derived PaO2/FIO2 values were used in place of missing PaO2/FIO2 values) were compared in a different cohort (n = 1,205). The best SpO2/FIO2-PaO2/FIO2 relationship in 1,703 SpO2/FIO2-to-PaO2/FIO2 data pairs was a linear regression equation of ln[PF] regressed on ln[SF]. This equation identified children with a PaO2/FIO2 less than or equal to 200 with a specificity of 73% and sensitivity of 61% in children with SpO2 less than 97% (92% and 33%, respectively, when SpO2 ≥ 97%) in the validation cohort. PaO2/FIO2 derived from SpO2/FIO2 (derived PaO2/FIO2) was better at predicting PICU mortality (area under receiver operating characteristic curve, 0.64; 95% CI, 0.55-0.73) compared with the original PaO2/FIO2 (area under receiver operating characteristic curve, 0.54; 95% CI, 0.49-0.59; p = 0.02). However, there was no difference in the original and derived Pediatric Index of Mortality-3 scores and their discriminatory ability for mortality.
CONCLUSIONS: SpO2-based metrics perform no worse than arterial blood gas-based metrics in mortality prediction models. Future Pediatric Index of Mortality score versions may be improved by the inclusion of risk factors based on oxygen saturation values, especially in settings where PaO2 values are missing in a significant proportion of cases.

Entities:  

Mesh:

Year:  2017        PMID: 28121834     DOI: 10.1097/PCC.0000000000001075

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

Review 1.  Biomarkers in pediatric acute respiratory distress syndrome.

Authors:  Erin F Carlton; Heidi R Flori
Journal:  Ann Transl Med       Date:  2019-10

2.  Functional outcomes at PICU discharge in hemato-oncology children at a tertiary oncology center in Hong Kong.

Authors:  Karen K Y Leung; Samiran Ray; Godfrey C F Chan; Kam Lun Hon
Journal:  Int J Clin Oncol       Date:  2022-09-23       Impact factor: 3.850

3.  Fraction of Inspired Oxygen With Low-Flow Versus High-Flow Devices: A Simulation Study.

Authors:  Yuki Kojima; Ryozo Sendo; Naoko Okayama; Junichiro Hamasaki
Journal:  Cureus       Date:  2022-05-18

4.  A new method for identifying the acute respiratory distress syndrome disease based on noninvasive physiological parameters.

Authors:  Pengcheng Yang; Taihu Wu; Ming Yu; Feng Chen; Chunchen Wang; Jing Yuan; Jiameng Xu; Guang Zhang
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240

5.  SpO2/FiO2 as a predictor of high flow nasal cannula outcomes in children with acute hypoxemic respiratory failure.

Authors:  Ga Eun Kim; Sun Ha Choi; Mireu Park; Jae Hwa Jung; Myeongjee Lee; Soo Yeon Kim; Min Jung Kim; Yoon Hee Kim; Kyung Won Kim; Myung Hyun Sohn
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.